Product Description
to prevent or arrest the development and progression of neurodegenerative changes
Mechanisms of Action: GHRH Antagonist
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BCN Peptides
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Spain
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Diabetic Retinopathy
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-505791-30-01 |
RETISOM | P3 |
Recruiting |
Diabetic Retinopathy |
2025-05-01 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|